Article-Journal

Current practice in reporting internal dosimetry for [177Lu]Lu-DOTATATE therapy: a systematic review
Initiatives have been taken to standardize the reporting of dosimetry results in image-derived radiation absorbed dose in …
Jun 1, 2026
Cite DOI
Reference tissue uptake of [18F]PSMA-1007 in positron emission tomography of recurrent prostate cancer
Semi-quantitative uptake measurements are part of the PROMISE framework for PET/CT interpretation of tracers targeting the …
Apr 23, 2026
Cite DOI
Pulling Together: A 5-Year Plan to Improve Theranostic Outcomes by Improving the Accuracy of Dosimetry-An FNIH Joint Academic, Clinical, and Industrial Collaboration
No abstract available
Apr 2, 2026
Cite DOI
Progression-Free and Overall Survival After KRd Consolidation in FDG PET/CT Positive Patients After ASCT: A Phase II Study (CONPET)
In multiple myeloma, 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) positivity after first-line autologous stem cell …
Mar 1, 2026
Cite DOI
Assessing the feasibility of quantitative SPECT imaging for low 212Pb activity concentrations using anthropomorphic phantoms
Lead-212 (212Pb) is being investigated for alpha therapies, but it can be challenging to image. To investigate the quantitative …
Jan 5, 2026
Cite DOI
Comparison of imaging-based bone marrow dosimetry methodologies and their dose-effect relationships in [177Lu]Lu-PSMA-617 RLT including a novel method with active marrow localization
Establishing accurate methods for red marrow (RM) dosimetry is an important step toward patient-specific treatment guidance. We …
Dec 4, 2025
Cite DOI
Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
Before performing 177Lu-DOTATATE therapy for neuroendocrine tumors, somatostatin receptor (SSTR) PET imaging is currently used to …
May 22, 2025
Cite DOI
Rethinking Dosimetry: A European Perspective
Radiopharmaceutical therapy (RPT) is entering a new era of personalization, driven by advances in molecular imaging, …
May 22, 2025
Cite DOI
Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer
Metastatic castration-resistant prostate cancer (mCRPC) frequently leads to bone and soft tissue metastases, leading to poor prognosis. …
May 21, 2025
Cite DOI
First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer
AB001, a prostate-specific membrane antigen (PSMA)-targeted small molecule labeled with the in vivo-generating α-emitter 212Pb, was …
May 1, 2025
Cite DOI